Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Gallo

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Francesco Perrone, Paolo Chiodini, et al.
Cancer|May 14, 2008
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomyLuca Cindolo, Paolo Chiodini, Ciro Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancerFrancesco Perrone, Ermelinda De Maio, Paolo Maione, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) studySandro Pignata, Enrico Breda, Giovanni Scambia, et al.
Kidney International|May 25, 2012
The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology careLuca De Nicola, Roberto Minutolo, Paolo Chiodini, et al.
The Lancet. Oncology|May 7, 2003
Statistical design in phase II clinical trials and its application in breast cancerFrancesco Perrone, Massimo Di Maio, Ermelinda De Maio, et al.
Journal of Clinical Gastroenterology|February 19, 2003
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II studyBruno Daniele, Gerardo Rosati, Rosa Tambaro, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 18, 2011
High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort StudyFerdinando C Sasso, Paolo Chiodini, Ornella Carbonara, et al.
Tumori|November 10, 2005
Cost of insurance policies for investigator-initiated cancer clinical trials in ItalyFrancesco Perrone, Maurizio Marangolo, Francesco Di Costanzo, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Francesco Perrone, Paolo Chiodini, et al.
Cancer|May 14, 2008
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomyLuca Cindolo, Paolo Chiodini, Ciro Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancerFrancesco Perrone, Ermelinda De Maio, Paolo Maione, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) studySandro Pignata, Enrico Breda, Giovanni Scambia, et al.
Kidney International|May 25, 2012
The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology careLuca De Nicola, Roberto Minutolo, Paolo Chiodini, et al.
The Lancet. Oncology|May 7, 2003
Statistical design in phase II clinical trials and its application in breast cancerFrancesco Perrone, Massimo Di Maio, Ermelinda De Maio, et al.
Journal of Clinical Gastroenterology|February 19, 2003
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II studyBruno Daniele, Gerardo Rosati, Rosa Tambaro, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 18, 2011
High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort StudyFerdinando C Sasso, Paolo Chiodini, Ornella Carbonara, et al.
Tumori|November 10, 2005
Cost of insurance policies for investigator-initiated cancer clinical trials in ItalyFrancesco Perrone, Maurizio Marangolo, Francesco Di Costanzo, et al.
Pageof 12